Skip to main content

Advertisement

SpringerLink
Log in

Inflammation in IgA nephropathy

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Immunoglobulin A nephropathy (IgAN) is the most frequently occurring primary glomerulonephritis in Caucasian and Asian populations. Nonetheless, therapeutic recommendations are based on weak evidence, large controlled trials are scarce and, in particular, the additional value of immunosuppression beyond comprehensive supportive measures is not well-established. The use of immunosuppressants is supported by experimental insights into IgAN pathogenesis that suggest an autoimmune component in disease development. The so-called “multi-hit” theory comprises multiple steps, starting with defective glycosylation of IgA subclass IgA1 that results in overproduction of galactose-deficient IgA1 (Gd-IgA1), occurrence of anti-Gd-IgA1 autoantibodies, and mesangial deposition of nephritogenic immune complexes. This eventually results in an increased mesangial cell proliferation, inflammatory responses, and complement activation. Recent genome-wide association studies have identified several susceptibility genes, many of which support the “multi-hit” concept. In light of these discoveries, it is astonishing that the vast majority of adult IgAN patients obviously do not need and/or benefit from immunosuppressive therapies in the first place. In fact, a number of supportive measures are highly effective in reducing the risk for disease progression in many patients. These measures need to be optimized before immunosuppression should be considered at all. In this review we focus on the underlying pathogenetic cornerstones and the central question of whether systemic inflammation in adult IgAN patients should be treated. Treatment options in children with IgAN are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368:2402–2414

    Article  CAS  PubMed  Google Scholar 

  2. Floege J, Eitner F (2011) Current therapy for IgA nephropathy. J Am Soc Nephrol 22:1785–1794

    Article  CAS  PubMed  Google Scholar 

  3. Schena FP (1990) A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 89:209–215

    Article  CAS  PubMed  Google Scholar 

  4. Berger J, Hinglais N (1968) Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 74:694–695

    CAS  Google Scholar 

  5. McGrogan A, Franssen CF, de Vries CS (2011) The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 26:414–430

    Article  PubMed  Google Scholar 

  6. Berthoux F (1990) Annual incidence of glomerulonephritis in the extended Rhone-Alpes region in 1987–1988. Presse Med 19:1417

    CAS  PubMed  Google Scholar 

  7. Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP, Italian Immunopathology Group, Italian Society of Nephrology (2004) The Italian experience of the national registry of renal biopsies. Kidney Int 66:890–894

    Article  PubMed  Google Scholar 

  8. Hanko JB, Mullan RN, O’Rourke DM, McNamee PT, Maxwell AP, Courtney AE (2009) The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 24:3050–3054

    Article  PubMed  Google Scholar 

  9. Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H (2009) The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant 24:870–876

    Article  PubMed  Google Scholar 

  10. Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, Tsuruya K, Kiyomoto H, Iida H, Sasaki T, Higuchi M, Hattori M, Oka K, Kagami S, Nagata M, Kawamura T, Honda M, Fukasawa Y, Fukatsu A, Morozumi K, Yoshikawa N, Yuzawa Y, Matsuo S, Kiyohara Y, Joh K, Taguchi T, Makino H, Committee for Standardization of Renal Pathological Diagnosis and Working Group for Renal Biopsy Database (2011) Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol 15:493–503

    Article  PubMed  Google Scholar 

  11. Magistroni R, D’Agati VD, Appel GB, Kiryluk K (2015) New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 88:974–989

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Levy M (1989) Familial cases of Berger’s disease and anaphylactoid purpura: more frequent than previously thought. Am J Med 87:246–248

    Article  CAS  PubMed  Google Scholar 

  13. Julian BA, Quiggins PA, Thompson JS, Woodford SY, Gleason K, Wyatt RJ (1985) Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 312:202–208

    Article  CAS  PubMed  Google Scholar 

  14. Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, Viola BF, Nicola B, Movilli E, Sandrini M, Campanini M, Maiorca R (1999) Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis 33:857–865

    Article  CAS  PubMed  Google Scholar 

  15. Karnib HH, Sanna-Cherchi S, Zalloua PA, Medawar W, D’Agati VD, Lifton RP, Badr K, Gharavi AG (2007) Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant 22:772–777

    Article  CAS  PubMed  Google Scholar 

  16. Tsuboi N, Kawamura T, Okonogi H, Ishii T, Utsunomiya Y, Hosoya T (2011) Discordant clinicopathological features in monozygotic twins with IgA nephropathy. Nephrol Dial Transplant 26:4146–4148

    Article  PubMed  Google Scholar 

  17. Schena FP, Scivittaro V, Ranieri E, Sinico R, Benuzzi S, Di Cillo M, Aventaggiato L (1993) Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy. Clin Exp Immunol 92:139–144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, Kumar A, Peden JF, Maxwell PH, Morris DL, Padmanabhan S, Vyse TJ, Zawadzka A, Rees AJ, Lathrop M, Ratcliffe P (2015) HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 21:1791–1797

    Article  Google Scholar 

  19. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321–327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yu XQ, Li M, Zhang H, Low HQ, Wei X, Wang JQ, Sun LD, Sim KS, Li Y, Foo JN, Wang W, Li ZJ, Yin XY, Tang XQ, Fan L, Chen J, Li RS, Wan JX, Liu ZS, Lou TQ, Zhu L, Huang XJ, Zhang XJ, Liu ZH, Liu JJ (2011) A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44:178–182

    Article  PubMed  Google Scholar 

  21. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ambruzs JM, Walker PD, Larsen CP (2014) The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 9:265–270

    Article  PubMed  Google Scholar 

  23. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG (2012) Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8:e1002765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:17951–803

    Article  Google Scholar 

  25. Conley ME, Cooper MD, Michael AF (1980) Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66:1432143–6

    Article  Google Scholar 

  26. Scinicariello F, Attanasio R (2001) Intraspecies heterogeneity of immunoglobulin alpha-chain constant region genes in rhesus macaques. Immunology 103:441–448

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J (2001) Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60:969–973

  28. Novak J, Julian BA, Tomana M, Mestecky J (2008) IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 28:78–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H (2012) The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790–796

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104:73–81

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcón GS, Kimberly RP, Tomino Y, Mestecky J, Novak J (2008) IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118:629–639

  32. Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J, Raska M (2015) N-acetylgalactosaminide alpha2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant 30:234–238

  33. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668–1677

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, Renfrow MB, Novak L, Wyatt RJ, Novak J (2008) Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 31:29–37

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579–1587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lai KN, Tang SC, Guh JY, Chuang TD, Lam MF, Chan LY, Tsang AW, Leung JC (2003) Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin- angiotensin system. J Am Soc Nephrol 14:3127–3137

    Article  CAS  PubMed  Google Scholar 

  37. Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, Monteiro RC (2001) Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194:417–425

  38. Launay P, Grossetête B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, Patey-Mariaud de Serre N, Lehuen A, Monteiro RC (2000) Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 191:1999–2009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD (2002) Podocytopenia and disease severity in IgA nephropathy. Kidney Int 61:1475–1485

    Article  PubMed  Google Scholar 

  40. Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Tam KY, Xiao J, Lai FM, Tang SC (2009) Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 24:62–72

    Article  CAS  PubMed  Google Scholar 

  41. Daha MR, van Kooten C (2016) Role of complement in IgA nephropathy. J Neprol 29:1–4

    CAS  Google Scholar 

  42. Haas M (2005) Histology and immunohistology of IgA nephropathy. J Nephrol 18:676–680

    PubMed  Google Scholar 

  43. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR (2006) Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724–1734

    Article  CAS  PubMed  Google Scholar 

  44. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR (2001) Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 167:2861–2868

    Article  CAS  PubMed  Google Scholar 

  45. Zhu L, Zhai YL, Wang FM, Hou P, Lv JC, Xu DM, Shi SF, Liu LJ, Yu F, Zhao MH, Novak J, Gharavi AG, Zhang H (2015) Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. J Am Soc Nephrol 26:195–204

    Google Scholar 

  46. Kidney Disease/Improving Global Outcomes (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2(2). http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf

  47. Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH (2009) ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 63:880–888

    Article  CAS  PubMed  Google Scholar 

  48. Floege J, Feehally J (2013) Treatment of IgA nephropathy and Henoch–Schonlein nephritis. Nat Rev Nephrol 9:320–327

  49. Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F, Trial Group ESCAPE (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650

  50. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J, STOP–IgAN Investigators (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225–2236

    Article  CAS  PubMed  Google Scholar 

  51. Manno C, Torres DD, Rossini M, Pesce F, Schena FP (2010) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694–3701

    Article  Google Scholar 

  52. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G (2008) Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19:1213–1224

    Article  PubMed  PubMed Central  Google Scholar 

  53. J L, D X, Perkovic V, Ma X, Johnson DW, Woodward M, Levin A, Zhang H, Wang H, TESTING Study Group (2012) Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23:1108–1116

    Article  Google Scholar 

  54. Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF (2015) Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 3:CD003965

    Google Scholar 

  55. Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, Matsushima M, Utsunomiya Y, Ogura M, Yokoo T, Okonogi H, Ishii T, Hamaguchi A, Ueda H, Furusu A, Horikoshi S, Suzuki Y, Shibata T, Yasuda T, Shirai S, Imasawa T, Kanozawa K, Wada A, Yamaji I, Miura N, Imai H, Kasai K, Soma J, Fujimoto S, Matsuo S, Tomino Y, Group SIANS (2014) A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 29:1546–1553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Feehally J, Coppo R, Troyanov S, Bellur SS, Cattran D, Cook T, Roberts IS, Verhave JC, Camilla R, Vergano L, Egido J, Wiecek A, Karkoszka H, Tesar V, Maixnerova D, Ots-Rosenberg M, Quaglia M, Rollino C, Magistroni R, Cusinato S, Cravero R, Peruzzi L, Lundberg S, Gesualdo L, Cancarini G, Feriozzi S, Ferrario F, VALIGA study of ERA-EDTA Immunonephrology Working G roup (2016) Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. Nephron 132:15–24

    Article  CAS  PubMed  Google Scholar 

  57. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R, VALIGA study of the ERA-EDTA Immunonephrology Working Group (2015) Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 26:2248–2258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883–887

    Article  CAS  PubMed  Google Scholar 

  59. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157–163

    Article  CAS  PubMed  Google Scholar 

  60. Sarcina C, Tinelli C, Ferrario F, Visciano B, Pani A, De Silvestri A, De Simone I, Del Vecchio L, Terraneo V, Furiani S, Santagostino G, Corghi E, Pozzi C (2016) Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy. PLoS One 11:e0158584

    Article  PubMed  PubMed Central  Google Scholar 

  61. Ballardie FW, Roberts IS (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148

    CAS  PubMed  Google Scholar 

  62. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2110:1783–1790

    Article  Google Scholar 

  63. Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C (2016) Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am soc Nephrol 11:973–981

    Article  PubMed  PubMed Central  Google Scholar 

  64. Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, Wang C, Li S, Zhang J, Zhang J, Liu L, Shi S, Wang S, Chen M, Cui Z, Chen N, Yu X, Zhao M, Wang H (2013) Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol 24:2118–2125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L (2002) A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 82:796–801

    PubMed  Google Scholar 

  66. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68:802–812

    Article  CAS  PubMed  Google Scholar 

  67. Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77:543–549

    Article  CAS  PubMed  Google Scholar 

  68. Liu X, Dewei D, Sun S, Xu G, Liu H, He L, Zhang P (2014) Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J Clin Pharmacol Ther 52:95–102

    Article  CAS  PubMed  Google Scholar 

  69. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF (2004) Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842–1849

    Article  CAS  PubMed  Google Scholar 

  70. Frisch G, Lin J, Rosenstock J, Markowitz G, D’Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G (2005) Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 20:2139–2145

    Article  CAS  PubMed  Google Scholar 

  71. Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ (2015) Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66:783–791

    Article  CAS  PubMed  Google Scholar 

  72. Lv J, Zhang H, Cui Z, Su T, Zhang Y, Wang H (2008) Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 23:2868–2872

    Article  CAS  PubMed  Google Scholar 

  73. Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC (2016) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. doi:10.1681/ASN.2016060640

    Google Scholar 

  74. Peng W, Tang Y, Jiang Z, Li Z, Mi X, Qin W (2016) The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA). Medicine 95:e4731

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Masutani K, Tsuchimoto A, Yamada T, Hirakawa M, Mitsuiki K, Katafuchi R, Hirakata H, Kitazono T, Tsuruya K, West Japan Study Group for Therapy of IgA Nephropathy Investigators (2016) Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial. Clin Exp Nephrol 20:896–903

    Article  CAS  PubMed  Google Scholar 

  76. Kuppe C, van Roeyen C, Leuchtle K, Kabgani N, Vogt M, Van Zandvoort M, Smeets B, Floege J, Gröne H, Moeller MJ (2016) Investigations of glucocorticoid action in GN. J Am Soc Nephrol. doi:10.1681/ASN.2016010060

    PubMed  Google Scholar 

  77. Ma TK, McAdoo SP, Tam FW (2016) Spleen tyrosine kinase: a crucial player and potential therapeutic target in renal disease. Nephron 133:261-9

  78. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D (2006) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 74:2006–2015

    Article  Google Scholar 

  79. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14:R33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Rojas-Rivera J, Fernandez-Juarez G, Praga M (2015) Rapidly progressive IgA nephropathy: a form of vasculitis or a complement-mediated disease? Clin Kidney J 8:477–481

    Article  PubMed  PubMed Central  Google Scholar 

  81. Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H, Working Group of the International IgA Nephropathy Network and the Renal Pathology Society (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77:921–927

    Article  CAS  PubMed  Google Scholar 

  82. Ikezumi Y1, Suzuki T, Imai N, Ueno M, Narita I, Kawachi H, Shimizu F, Nikolic-Paterson DJ, Uchiyama M (2006) Histological differences in new-onset IgA nephropathy between children and adults. Nephrol Dial Transplant 21:3466–3474

    Article  PubMed  Google Scholar 

  83. D’Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179–196

    Article  PubMed  Google Scholar 

  84. Nozawa R, Suzuki J, Takahashi A, Isome M, Kawasaki Y, Suzuki S, Suzuki H (2005) Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol 64:171–179

    Article  CAS  PubMed  Google Scholar 

  85. Coppo R (2008) Pediatric IgA nephropathy: clinical and therapeutic perspectives. Semin Nephrol 28:18–26

    Article  PubMed  Google Scholar 

  86. Kamei K, Harada R, Hamada R, Sakai T, Hamasaki Y, Hataya H, Ito S, Ishikura K, Honda M (2016) Proteinuria during follow-up period and long-term renal survival of childhood IgA nephropathy. PLoS One 11:e0150885

    Article  PubMed  PubMed Central  Google Scholar 

  87. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M, The Japanese Pediatric IgA Nephropathy Treatment Study Group (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 10:101–109

    CAS  PubMed  Google Scholar 

  88. Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, Hataya H, Honda M, Iijima K, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group (2011) Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 6:1301–1307

    Article  PubMed  PubMed Central  Google Scholar 

  89. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H, Japanese Pediatric IgA Nephropathy Treatment Study Group (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1:511–517

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Clinical Immunology, RWTH Aachen University, Pauwelsstr. 30, 52057, Aachen, Germany

    Thomas Rauen & Jürgen Floege

Authors
  1. Thomas Rauen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen Floege
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Floege.

Ethics declarations

Conflict of interest

J. Floege has received consultancy honoraria from Pharmalink, Sweden. T. Rauen has no conflicts of interest to declare.

Additional information

Answers:

1. c

2. e

3. b

4. a

5. c

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rauen, T., Floege, J. Inflammation in IgA nephropathy. Pediatr Nephrol 32, 2215–2224 (2017). https://doi.org/10.1007/s00467-017-3628-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-017-3628-1

Keywords

Search

Navigation